Vical Incorporated (VICL) EPS Estimated At $-0.20

February 12, 2018 - By Henry Gaston

 Vical Incorporated (VICL) EPS Estimated At $ 0.20

Analysts expect Vical Incorporated (NASDAQ:VICL) to report $-0.20 EPS on March, 8.They anticipate $0.05 EPS change or 20.00 % from last quarter’s $-0.25 EPS. After having $-0.27 EPS previously, Vical Incorporated’s analysts see -25.93 % EPS growth. The stock decreased 0.69% or $0.01 during the last trading session, reaching $1.44. About 26,167 shares traded. Vical Incorporated (NASDAQ:VICL) has declined 38.65% since February 12, 2017 and is downtrending. It has underperformed by 55.35% the S&P500.

Vical Incorporated (NASDAQ:VICL) Ratings Coverage

Among 2 analysts covering Vical (NASDAQ:VICL), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vical had 7 analyst reports since July 19, 2016 according to SRatingsIntel. The stock of Vical Incorporated (NASDAQ:VICL) earned “Buy” rating by H.C. Wainwright on Tuesday, November 21. On Monday, January 22 the stock rating was maintained by H.C. Wainwright with “Buy”. The rating was maintained by H.C. Wainwright with “Buy” on Wednesday, August 9. The stock has “Buy” rating by H.C. Wainwright on Monday, June 12. H.C. Wainwright maintained the shares of VICL in report on Thursday, February 1 with “Buy” rating. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, July 19. Rodman \u0026 Renshaw reinitiated the shares of VICL in report on Monday, June 12 with “Buy” rating.

Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company has market cap of $26.78 million. It is developing various DNA vaccines and other therapeutics, such as VCL-HB01 therapeutic vaccine for herpes simplex virus-2 that is in Phase II clinical trial to prevent and protect against lesion recurrence; VL-2397 antifungal program, which is in Phase I clinical trial for the treatment of invasive fungal infections; and CyMVectin prophylactic vaccine for CMV that is in preclinical stage for the prevention of fetal transmission during pregnancy. It currently has negative earnings. The firm also engages in contract manufacturing of plasmid investigational products for various clients.

More notable recent Vical Incorporated (NASDAQ:VICL) news were published by: which released: “Astellas and Vical Announce Top-Line Results for Phase 3 Trial of …” on January 22, 2018, also with their article: “Vical Announces Restructuring to Focus Resources on HSV-2 and Antifungal …” published on January 30, 2018, published: “Vical Incorporated (NASDAQ:VICL) Stock Worth Watching” on January 24, 2018. More interesting news about Vical Incorporated (NASDAQ:VICL) were released by: and their article: “Biotech Analysis Central Pharma News: Bellicum’s Clinical Hold, Vical’s …” published on January 31, 2018 as well as‘s news article titled: “Motif Bio PLC, Spero Therapeutics, Inc. and Vical Incorporated Join …” with publication date: January 29, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.